Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives

Autoimmune hemolytic anemia (AIHA) is increasingly observed after allogeneic hematopoietic stem cell transplantation (allo-HSCT), with a reported incidence between 4% and 6%. The disease is generally severe and refractory to standard therapy, with high mortality, and there are neither defined therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Barcellini, Wilma, Fattizzo, Bruno, Zaninoni, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690850/
https://www.ncbi.nlm.nih.gov/pubmed/31496855
http://dx.doi.org/10.2147/JBM.S190327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6690850/
https://www.ncbi.nlm.nih.gov/pubmed/31496855
http://dx.doi.org/10.2147/JBM.S190327

Ejemplares similares